These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 12933583)

  • 21. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis.
    Viti F; Tarli L; Giovannoni L; Zardi L; Neri D
    Cancer Res; 1999 Jan; 59(2):347-52. PubMed ID: 9927045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo tumor delivery of a recombinant single chain Fv::tumor necrosis factor-alpha fusion [correction of factor: a fusion] protein.
    Cooke SP; Pedley RB; Boden R; Begent RH; Chester KA
    Bioconjug Chem; 2002; 13(1):7-15. PubMed ID: 11792173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF.
    Schwager K; Hemmerle T; Aebischer D; Neri D
    J Invest Dermatol; 2013 Mar; 133(3):751-758. PubMed ID: 23096716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo.
    Villa A; Trachsel E; Kaspar M; Schliemann C; Sommavilla R; Rybak JN; Rösli C; Borsi L; Neri D
    Int J Cancer; 2008 Jun; 122(11):2405-13. PubMed ID: 18271006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective occlusion of tumor blood vessels by targeted delivery of an antibody-photosensitizer conjugate.
    Fabbrini M; Trachsel E; Soldani P; Bindi S; Alessi P; Bracci L; Kosmehl H; Zardi L; Neri D; Neri P
    Int J Cancer; 2006 Apr; 118(7):1805-13. PubMed ID: 16217760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.
    Pretto F; Elia G; Castioni N; Neri D
    Cancer Immunol Immunother; 2014 Sep; 63(9):901-10. PubMed ID: 24893857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine.
    Mortara L; Orecchia P; Castellani P; Borsi L; Carnemolla B; Balza E
    Cancer Med; 2013 Aug; 2(4):478-87. PubMed ID: 24156020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficiency of recombinant human TNF in human cancer therapy.
    Lejeune FJ; Liénard D; Matter M; Rüegg C
    Cancer Immun; 2006 Mar; 6():6. PubMed ID: 16551058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2.
    Schliemann C; Palumbo A; Zuberbühler K; Villa A; Kaspar M; Trachsel E; Klapper W; Menssen HD; Neri D
    Blood; 2009 Mar; 113(10):2275-83. PubMed ID: 19005180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer.
    Hemmerle T; Neri D
    Int J Cancer; 2014 Jan; 134(2):467-77. PubMed ID: 23818211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted tumor therapy with a fusion protein of an antiangiogenic human recombinant scFv and yeast cytosine deaminase.
    Schellmann N; Panjideh H; Fasold P; Bachran D; Bachran C; Deckert PM; Fuchs H
    J Immunother; 2012 Sep; 35(7):570-8. PubMed ID: 22892453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy.
    Mårlind J; Kaspar M; Trachsel E; Sommavilla R; Hindle S; Bacci C; Giovannoni L; Neri D
    Clin Cancer Res; 2008 Oct; 14(20):6515-24. PubMed ID: 18927291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance.
    Melkko S; Halin C; Borsi L; Zardi L; Neri D
    Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1485-90. PubMed ID: 12459375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular-targeted TNFα improves tumor blood vessel function and enhances antitumor immunity and chemotherapy in colorectal cancer.
    Lu L; Li ZJ; Li LF; Wu WK; Shen J; Zhang L; Chan RL; Yu L; Liu YW; Ren SX; Chan KM; Cho CH
    J Control Release; 2015 Jul; 210():134-46. PubMed ID: 26003042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties.
    Gafner V; Trachsel E; Neri D
    Int J Cancer; 2006 Nov; 119(9):2205-12. PubMed ID: 16823838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells.
    Scherf U; Benhar I; Webber KO; Pastan I; Brinkmann U
    Clin Cancer Res; 1996 Sep; 2(9):1523-31. PubMed ID: 9816329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toxicity and antitumor activity of interferon gamma alone and in combinations with TNFalpha and melphalan in isolated limb perfusion in the BN175 sarcoma tumor model in rats.
    Manusama ER; De Wilt JH; Ten Hagen TL; Marquet RL; Eggermont AM
    Oncol Rep; 1999; 6(1):173-7. PubMed ID: 9864423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
    Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
    J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate.
    Berndorff D; Borkowski S; Sieger S; Rother A; Friebe M; Viti F; Hilger CS; Cyr JE; Dinkelborg LM
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7053s-7063s. PubMed ID: 16203802
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.